普瑞巴林在慢性疼痛治療中的應(yīng)用
發(fā)布時(shí)間:2018-06-23 來(lái)源: 人生感悟 點(diǎn)擊:
[摘要] 目的 探討普瑞巴林在慢性疼痛治療中的應(yīng)用效果。 方法 選取2014年2月~2016年4月收治的帶狀皰疹后遺神經(jīng)痛患者52例,依據(jù)雙盲分組法隨機(jī)分兩組,對(duì)照組26例給予常規(guī)藥物布洛芬緩釋膠囊治療,觀察組26例給予普瑞巴林治療,比較兩組臨床效果。 結(jié)果 治療前兩組疼痛強(qiáng)度、睡眠質(zhì)量無(wú)顯著差異(P>0.05),服藥后兩組疼痛強(qiáng)度緩解、睡眠質(zhì)量提高(P<0.05),但觀察組較對(duì)照組更具優(yōu)勢(shì)(P<0.05);兩組發(fā)生不良反應(yīng)無(wú)顯著差異(P>0.05)。 結(jié)論 普瑞巴林在慢性疼痛治療中效果顯著,未見(jiàn)嚴(yán)重不良反應(yīng),安全應(yīng)用。
[關(guān)鍵詞] 慢性疼痛;普瑞巴林;作用機(jī)制;不良反應(yīng)
[中圖分類號(hào)] R747.9 [文獻(xiàn)標(biāo)識(shí)碼] B [文章編號(hào)] 1673-9701(2018)08-0116-03
Application of pregabalin in the treatment of chronic pain
SUN Lei YAO Juan LI Qunlin TANG Shuguang
Department of Pain, the First Hospital of Kunming,Kunming 650011,China
[Abstract] Objective To investigate the effect of pregabalin in the treatment of chronic pain. Methods 52 patients with postherpetic neuralgia after shingles of the patients with chronic pain admitted from February 2014 to April 2016 were selected and divided into two groups randomly according to the double-blind grouping method. In the control group, 26 patients were given conventional drug ibuprofen release capsule treatment. And 26 patients in the observation group were given pregabalin treatment. The clinical effect between the two groups was compared. Results There was no significant difference in the pain intensity and sleep quality between the two groups before treatment(P>0.05). The pain intensity was relieved and the quality of sleep was improved in two groups after taking medicine(P<0.05), while the observation group had more advantages than the control group(P<0.05). There was no significant difference in the adverse reactions between the two groups(P>0.05). Conclusion Pregabalin has significant effect in the treatment of chronic pain without serious adverse reactions and should be safely used.
[Key words] Chronic pain;Pregabalin;Mechanism;Clinical efficacy;Adverse reactions
普瑞巴林是瑞輝公司生產(chǎn)的受體激動(dòng)劑,作為歐美公認(rèn)的治療帶狀皰疹與糖尿病性外周神經(jīng)痛的首個(gè)藥物,受到醫(yī)學(xué)界的高度重視[1]。自2004年普瑞巴林應(yīng)用到臨床實(shí)踐以來(lái),在神經(jīng)性疼痛治療中起到舉足輕重的作用,受到疼痛領(lǐng)域的關(guān)注,當(dāng)前歐美地區(qū)已超出40個(gè)國(guó)家將普瑞巴林投入到神經(jīng)性疼痛治療中[2]。我國(guó)對(duì)普瑞巴林藥物試驗(yàn)研究相對(duì)滯后,但已將普瑞巴林應(yīng)用到部分慢性疼痛治療中,現(xiàn)收集并整合我院收治的52例帶狀皰疹后遺神經(jīng)痛患者,分析普瑞巴林治療效果,現(xiàn)報(bào)道如下。
1資料與方法
1.1一般資料
資料來(lái)源于52例帶狀皰疹后遺神經(jīng)痛患者,均收治于2014年2月~2016年4月,無(wú)嚴(yán)重肝腎、心血管等功能障礙疾病,已排除神經(jīng)疾病、免疫功能低下等患者;選用雙盲分組法將患者分組,觀察組26例,女17例、男9例,年齡41~63歲、平均(52.3±3.8)歲,病程2~17個(gè)月、平均(7.1±2.4)月,受累部位分布:三叉神經(jīng)、肋間神經(jīng)、股神經(jīng)、臂叢神經(jīng)、腰骶神經(jīng)等,依次2、14、5、1、4例;對(duì)照組26例,女16例、男10例,年齡42~62歲、平均(53.1±4.1)歲,病程1~18個(gè)月、平均(7.3±2.7)月,按以上受累部位分布依次2、13、4、2、5例;兩組基礎(chǔ)資料比較無(wú)顯著差異(P>0.05),具有可比性。
1.2方法
對(duì)照組選用的藥物為布洛芬緩釋膠囊(中美天津史克制藥有限公司,國(guó)藥準(zhǔn)字H10900089),早晚各口服一次,0.3 g/次,持續(xù)服用4周;觀察組選用普瑞巴林膠囊(輝瑞制藥有限公司分裝,國(guó)藥準(zhǔn)字J20100102)治療,早晚各口服1次,初始劑量75 mg/次,服藥1周后如疼痛緩解,則按照初始劑量繼續(xù)服藥,若疼痛未改善,則增加劑量至早晚各口服1次,150 mg/次,持續(xù)服用4周,每周由醫(yī)師對(duì)患者進(jìn)行療效評(píng)估。
熱點(diǎn)文章閱讀